La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Larimar Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Larimar Therapeutics..

Larimar Therapeutics (NASDAQ:LRMR) Azioni, Catena delle Opzioni

Larimar Therapeutics

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Larimar Therapeutics, Inc. - Common Stock

Larimar Therapeutics Inc

Macro Economic Events

News

Econ #s

Economics

USA Nonfarm Payrolls For October 12K Vs 106K Est.; 223K Prior

Average Hourly Earnings Month Over Month (Oct) +0.4% vs +0.3% Est.

USA Unemployment Rate For October 4.1% Vs 4.1% Est.; 4.1% Prior

BHP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHP#NYSE">BHP</a>) has backtracked on remarks by its Chairman, Ken Mackenzie, about "moving on "from its <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/05/39068033/time-runs-out-for-bhp-deal-49-billion-acquisition-of-anglo-american-proves-too-complex-to-solve" rel="noreferrer noopener">failed $49 billion bid</a> for Anglo American (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/AAUKF#OTCQX">AAUKF</a>).
During BHP's annual shareholder meeting in Brisbane, MacKenzie had suggested that the Anglo American acquisition was a "nice to have, not a must-do" and indicated that BHP had put the deal behind them, <a target="_blank" href="https://www.theguardian.com/business/2024/oct/30/mining-firm-bhp-says-it-has-moved-on-from-failed-anglo-american-bid" rel="noreferrer noopener">reported</a> The Guardian.
"We thought there was an opportunity here to create something unique and special&#8230; But Anglo American shareholders had a different view, and so they moved on. And quite frankly, so have we," he stated.
However, BHP issued a <a target="_blank" href="https://www.bhp.com/news/media-centre/releases/2024/10/statement-regarding-anglo-american-plc" rel="noreferrer noopener">statement</a> clarifying that these comments were not intended to be a formal withdrawal from pursuing the deal under U.K. takeover regulations.
Following a discussion with the U.K. Takeover Panel, BHP confirmed that the panel would not treat MacKenzie's remarks as an official "no offer" statement, meaning the door remains open for a potential future bid.
Initially <a target="_blank" href="https://www.benzinga.com/markets/equities/24/04/38423994/worlds-largest-miner-bhp-bids-to-takeover-anglo-american-as-hunt-for-resources-intensify" rel="noreferrer noopener">proposed in April</a>, BHP's bid for Anglo American sought access to Anglo's lucrative copper assets in South America – as the price for the metal crucial in the green energy transition surged toward its <a target="_blank" href="https://www.benzinga.com/economics/macro-economic-events/24/05/38901984/silver-rockets-to-11-year-highs-copper-hits-record-peak-gold-approaches-historic-" rel="noreferrer noopener">yearly high in May</a>.
Despite the strategic fit, the deal faced hurdles, particularly concerning Anglo's South African assets. BHP hesitated to retain those due to regulatory complexities and economic risks associated with South Africa's business environment.
Unable to secure the deal, BHP turned to its key assets, looking to expand its Olympic Dam operation in South Australia and the Escondida mine in Chile; however, their domestic operations face challenges that could drive higher costs.
Australia's mining industry has been grappling with high labor expenses as worker shortages and competition drive wages upward. New labor laws, including the "Same Job, Same Pay" initiative, have raised concerns over their potential to <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/07/39647424/bhp-cuts-employee-incentives-misses-performance-goals" rel="noreferrer noopener">increase operational costs</a>.&nbsp;
At the Brisbane meeting, labor issues were a key focus, with hundreds of workers protesting BHP's stance on the new legislation and its effect on profitability.
Still, the company managed to increase its footprint in South America. In July, it <a target="_blank" href="https://www.benzinga.com/markets/equities/24/07/40031488/bhp-to-unlock-south-american-copper-riches-partners-with-lundin-for-filo-acquisition" rel="noreferrer noopener">announced a bid</a> for Filo Corp (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/FLMMF#OTCQX">FLMMF</a>). Through a 50-50 joint venture with Lundin Mining (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LUNMF#OTC">LUNMF</a>), BHP will spend $2 billion to acquire a 50% stake in the promising Filo del Sol copper project on the Chilean-Argentine border and a 50% stake in Lundin's Josemaria project.
The mandatory standstill on a new bid for Anglo American expires on November 29.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/10/41663633/biggest-gold-etf-posts-highest-monthly-inflows-in-2-5-years-as-investors-rush-to-" target="_blank" rel="noreferrer noopener">Biggest Gold ETF Posts Highest Monthly Inflows In 2.5 Years As Investors Rush To Safe Haven Ahead Of Presidential Election</a></li>
</ul>
Photo via Shutterstock

Large Cap

Commodities

Legal

AAUKF

FLMMF

LUNMF

BHP Backtracks Its Comments On Abandoning Anglo American Deal

Canaccord Genuity analyst Brian McNamara maintains Driven Brands Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRVN#NASDAQ">DRVN</a>) with a Buy and raises the price target from $20 to $21.

Price Target

Analyst Ratings

DRVN

Canaccord Genuity Maintains Buy on Driven Brands Hldgs, Raises Price Target to $21

JMP Securities analyst John Colantuoni maintains Booking Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>) with a Market Outperform and raises the price target from $5000 to $5400.

BKNG

JMP Securities Maintains Market Outperform on Booking Holdings, Raises Price Target to $5400

Earnings

Global Engine Group FY24 EPS $0.021; Revenue $6.33M

Canaccord Genuity analyst Whitney Ijem maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and raises the price target from $366 to $384.

ALNY

Canaccord Genuity Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $384

S&amp;W Seed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANW#NASDAQ">SANW</a>) reported quarterly losses of $(2.95) per share which missed the analyst consensus estimate of $(1.90) by 55.26 percent. This is a 2169.23 percent decrease over losses of $(0.13) per share from the same period last year. The company reported quarterly sales of $14.82 million which missed the analyst consensus estimate of $23.00 million by 35.57 percent. This is a 35.72 percent decrease over sales of $23.05 million the same period last year.

Earnings Misses

SANW

S&W Seed Q4 Adj $(2.95) Misses $(1.90) Estimate, Sales $14.82M Miss $23.00M Estimate

Friday,&nbsp;Cardinal Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) reported first-quarter 2025 adjusted EPS of $1.88, up 9% year over year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $1.62</a>.
Sales decreased 4% to $52.28 billion, beating the&nbsp;consensus of $50.90 billion. Adjusted operating earnings increased 12% to&nbsp;$625 million.
First-quarter revenue for the Pharmaceutical and Specialty Solutions segment decreased by 5% to&nbsp;$48.0 billion. Excluding the customer contract expiration, revenue increased by 16%, driven by brand and specialty pharmaceutical sales growth <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41679244/cardinal-health-reports-first-quarter-fiscal-year-2025-results-and-raises-fiscal-year-2025-outlook" rel="noreferrer noopener">from existing customers</a>.
Pharmaceutical and Specialty Solutions segment profit increased 16% to&nbsp;$530 million, driven by a higher contribution from brand and specialty products, including the earlier seasonal launch of COVID-19 vaccine distribution and positive generics program performance.
The Pharmaceutical and Specialty Solutions segment distributes branded and generic pharmaceuticals, specialty drugs, and OTC products and offers services for specialty pharmaceuticals, supporting both manufacturers and healthcare providers and pharmacy management services.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/09/40694838/opioid-settlement-drug-distributors-mckesson-cencora-cardinal-health-to-pay-300m-to-health-insurer" rel="noreferrer noopener">Opioid Settlement: Drug Distributors McKesson, Cencora, Cardinal Health To Pay $300M To Health Insurers</a>
Revenue for the Global Medical Products and Distribution segment increased 3% to&nbsp;$3.1 billion, driven by volume growth from existing customers.
Global Medical Products and Distribution (GMPD) segment profit decreased to&nbsp;$8 million, primarily due to higher manufacturing and health and welfare costs, largely offset by improved net inflationary impacts, including mitigation initiatives and growth from existing customers.
GMPD segment manufactures, sources, and distributes Cardinal Health brand medical, surgical, and laboratory products, as well as distributes medical, surgical and laboratory products known as national brand products
&#8220;We began fiscal 2025 by delivering strong operational and financial performance, led by the Pharmaceutical and Specialty Solutions segment,&#8221; said&nbsp;Jason Hollar, CEO of Cardinal Health.
&#8220;The strength and resiliency of our largest and most significant business continues to shine, giving us confidence to raise our fiscal 2025 enterprise guidance only a quarter into the year,&#8221; Hollar added.
Outlook:&nbsp;Cardinal Health has raised its fiscal year 2025 outlook for adjusted EPS to $7.75-$7.90 from <a target="_blank" href="https://www.benzinga.com/news/earnings/24/08/40364087/pharma-distribution-giant-cardinal-health-lifts-2025-guidance-after-q4-earnings-beat-raises-stock-b" rel="noreferrer noopener">prior guidance of</a> $7.55-$7.70 versus consensus of $7.63.
The guidance includes an update to the company&#8217;s Pharmaceutical and Specialty Solutions segment profit outlook to 4% to 6% growth, from 1% to 3% growth.
The company also updated its Global Medical Products and Distribution segment profit outlook to&nbsp;$140 million&nbsp;to&nbsp;$175 million, from approximately&nbsp;$175 million, primarily due to the impact of higher health and welfare costs.
Additionally, the company updated expectations for its adjusted free cash flow to&nbsp;$1.0 billion&nbsp;to&nbsp;$1.5 billion, from approximately&nbsp;$1.0 billion.
Price Action: CAH stock is trading 2.97% higher at $111.74 during the premarket session at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41661764/ford-to-halt-f-150-ev-production-for-7-weeks-next-month" target="_blank" rel="noreferrer noopener">Ford To Halt F-150 EV Production For 7 Weeks Next Month</a></li>
</ul>
Photo via Company

Guidance

Health Care

Movers

General

Cardinal Health Raises 2025 Profit Outlook Again, Helped By Strong Drug Distribution Business

JMP Securities analyst Jason Butler maintains argenx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) with a Market Outperform and raises the price target from $497 to $606.

ARGX

JMP Securities Maintains Market Outperform on argenx, Raises Price Target to $606

Exxon Mobil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) shares are trading higher after the company reported&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41679046/exxonmobil-announces-third-quarter-2024-results" rel="noreferrer noopener">third-quarter&nbsp;results</a>.&nbsp;
Total revenues and other income&nbsp;stood at&nbsp;$90.016 billion, missing the consensus of&nbsp;$93.938 billion.
Net production stood at 4,582 thousand oil-equivalent barrels per&nbsp;day, an increase of&nbsp;5%&nbsp;from the previous quarter, driven by increased volumes from Pioneer assets.
Read: <a target="_blank" href="https://www.benzinga.com/news/24/10/41659147/exxon-mobil-q3-preview-will-rising-production-cost-cuts-boost-earnings" rel="noreferrer noopener">Exxon Mobil Q3 Preview: Will Rising Production, Cost Cuts Boost Earnings?</a>
Adjusted net profit came in at&nbsp;$8.61 billion, down from&nbsp;$9.24 billion in the prior quarter. Adjusted EPS stood at&nbsp;$1.92,&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">beating the consensus of&nbsp;$1.88</a>.
Exxon&#8217;s&nbsp;capital and exploration expenditures stood at&nbsp;$7.16 billion in the&nbsp;third quarter, bringing year-to-date 2024 expenditures to&nbsp;$20 billion, in line with the <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">company&#8217;s full-year&nbsp;guidance&nbsp;of&nbsp;$28 billion.</a>
This month, ExxonMobil and HELLEniQ ENERGY completed Phase 1 of offshore Crete exploration,<a target="_blank" href="https://www.benzinga.com/markets/equities/24/10/41270873/exxonmobil-helleniq-energy-jv-completes-first-exploration-phase-in-crete-eyes-next-steps" rel="noreferrer noopener"> gathering 7,789 km of seismic data</a>.
Cost Reduction: The company achieved a cumulative structural cost savings of&nbsp;$11.3&nbsp; billion versus 2019, including an additional&nbsp;$1.6 billion&nbsp;of savings during the year and&nbsp;$0.6 billion&nbsp;during the quarter.
The company plans to deliver cumulative savings totaling&nbsp;$15 billion&nbsp;through the end of 2027 versus 2019.
Dividend Boost: Exxon raised its dividend per share by 4% to $0.99 from&nbsp;$0.95 per share, payable on December 10, to shareholders of record as of November 14.
The company&#8217;s year-to-date shareholder distributions totaled $26.1 billion, comprising $12.3 billion in dividends and $13.8 billion in share repurchases.
Darren Woods, chairman and chief executive officer, said, &#8220;Our industry-leading results continue to demonstrate how our enterprise-wide transformation is improving the structural earnings power of the company.&#8221;
&#8220;In the Upstream, we&#8217;ve doubled the profitability of the barrels we produce on a constant price basis. In Product Solutions, we&#8217;ve high-graded our refining footprint and increased high-value product sales.&#8221;
Investors can gain exposure to XOM via&nbsp;EA Series Trust Strive U.S. Energy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRLL#NYSE">DRLL</a>) and&nbsp;SPDR Select Sector Fund – Energy Select Sector&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>).
Price Action: XOM shares are up 2.07% at $119.20 premarket at the last check Friday.
Photo: Del Henderson Jr. via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41553999/exxon-mobils-golden-pass-lng-plant-gets-3-year-extension-amid-contractor-challenges-report" target="_blank" rel="noreferrer noopener">Exxon Mobil&#8217;s Golden Pass LNG Plant Gets 3-Year Extension Amid Contractor Challenges: Report</a></li>
</ul>

Equities

DRLL

Exxon Q3 Earnings: $11.3 Billion Cost Savings, Rising Production, Dividend Hike And More

Piper Sandler analyst Crispin Love maintains Blue Owl Cap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWL#NYSE">OWL</a>) with a Overweight and raises the price target from $23 to $25.

Piper Sandler Maintains Overweight on Blue Owl Cap, Raises Price Target to $25

JMP Securities analyst Nicholas Jones maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Market Outperform and raises the price target from $265 to $285.

AMZN

JMP Securities Maintains Market Outperform on Amazon.com, Raises Price Target to $285

Piper Sandler analyst Christopher Raymond maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Overweight and lowers the price target from $1242 to $1195.

REGN

Piper Sandler Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $1195

Yum China Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUMC#NYSE">YUMC</a>) — the parent company of KFC, Pizza Hut, and Taco Bell — will release earnings results for its third quarter, before the <a href="https://www.benzinga.com/quote/YUMC/earnings">opening bell on Monday, Nov. 4.</a>
Analysts expect the China-based company to report quarterly earnings at 67 cents per share, up from 59 cents per share in the year-ago period. Yum China projects to report revenue of $3.05 billion for the recent quarter, compared to $2.91 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Aug. 5, Yum China reported second-quarter results yesterday. Revenue increased 1% year over year to $2.68 billion, missing the consensus of $2.77 billion.
With the recent buzz around Yum China, some investors may be eyeing potential gains from the company's dividends too. As of now, Yum China offers an annual dividend yield of 1.45%, which is a quarterly dividend amount of 16 cents per share (64 cents a year).
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $413,531 or around 9,375 shares. For a more modest $100 per month or $1,200 per year, you would need $82,706 or around 1,875 shares.
To Calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend (64 cents in this case). So, $6,000 / $0.64 = 9,375 ($500 per month), and $1,200 / $0.64 = 1,875 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How That Works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
Price Action: Shares of Yum China fell 1.3% to close at $44.11 on Thursday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41654255/wall-streets-most-accurate-analysts-weigh-in-on-3-energy-stocks-with-over-8-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Energy Stocks With Over 8% Dividend Yields</a></li>
</ul>
Image: Unsplash

Long Ideas

Markets

Trading Ideas

YUMC

How To Earn $500 A Month From Yum China Stock Ahead Of Q3 Earnings

Imperial Oil (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IMO#AMEX">IMO</a>) reported quarterly earnings of C$2.33 per share which beat the analyst consensus estimate of C$2.00 by 16.5 percent. This is a 15.58 percent decrease over earnings of C$2.76 per share from the same period last year. The company reported quarterly sales of C$13.259 billion which missed the analyst consensus estimate of C$15.636 billion by 15.20 percent. This is a 4.75 percent decrease over sales of C$13.920 billion the same period last year.

Earnings Beats

Imperial Oil Q3 2024 GAAP EPS C$2.33 Beats C$2.00 Estimate, Sales C$13.259B Miss C$15.636B Estimate

DA Davidson analyst Linda Bolton Weiser maintains Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) with a Buy and lowers the price target from $130 to $81.

DA Davidson Maintains Buy on Estee Lauder Cos, Lowers Price Target to $81

2024 Guidance The Company currently estimates net income to be within a range of $7.18 to $7.28 per diluted share and FFO to be within a range of $12.80 to $12.90 per diluted share, excluding the $0.14 per diluted share of unrealized losses in fair value adjustments of the Klépierre exchangeable bonds and publicly traded equity instruments, net for the year ending December 31, 2024.&nbsp; &nbsp;&nbsp;
The following table provides the GAAP to non-GAAP reconciliation for the expected range of estimated net income attributable to common stockholders per diluted share to FFO per diluted share:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">For the year ending December 31, 2024</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Low</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">High</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">End</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">End</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Estimated net income attributable to common stockholders</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">per diluted share</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$7.18</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$7.28</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Depreciation and amortization including Simon's share</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">of unconsolidated entities</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">5.50</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">5.50</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Gain on acquisition of controlling interest, sale or</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">disposal of, or recovery on, assets and interest in</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">unconsolidated entities and impairment, net</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">(0.02)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">(0.02)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Estimated FFO per diluted share</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$12.66</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$12.76</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Unrealized losses in fair value adjustments</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">of the Klépierre exchangeable bonds and</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">publicly traded equity instruments, net</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">0.14</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">0.14</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Estimated FFO per diluted share, excluding unrealized</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">losses in fair value adjustments of the</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Klépierre exchangeable bonds and</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">publicly traded equity instruments, net</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$12.80</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$12.90</td>
</tr>
</tbody>
</table>
</figure>
 &nbsp;

Simon Property Group Sees FY24 EPS $7.18-$7.28 Vs $7.12 Est.; FFO $12.80-$12.90

Piper Sandler analyst Thomas Champion maintains Roblox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) with a Overweight and raises the price target from $54 to $65.

RBLX

Piper Sandler Maintains Overweight on Roblox, Raises Price Target to $65

Larimar started at outperform by Wedbush on FA drug candidate

Larimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside Potential

Larimar initiated with bullish view at Oppenheimer on lead drug

Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on Larimar Therapeutics (LRMR – Research Report) yesterday and set a price target ...

Bullish Outlook on Larimar Therapeutics Amid Upcoming OLE Data and Promising Drug Developments

Larimar Therapeutics GAAP EPS of -$0.24 beats by $0.14

Analyst Edward White from H.C. Wainwright reiterated a Buy rating on Larimar Therapeutics (LRMR – Research Report) and keeping the price target at ...

Promising Prospects for Larimar Therapeutics: Buy Rating on Innovative Friedreich's Ataxia Therapy

Analyst Cory Jubinville, PhD of LifeSci Capital maintained a Buy rating on Larimar Therapeutics (LRMR – Research Report), retaining the price targe...

Promising Developments and Strategic Vision Propel Buy Rating for Larimar Therapeutics

Larimar Therapeutics (LRMR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Samantha Se...

Optimistic Buy Rating for Larimar Therapeutics Amid Promising Data Release and Strategic Dose Increase

Larimar Therapeutics, Inc. ( ($LRMR) ) has realeased its Q3 earnings. Here is a breakdown of the information Larimar Therapeutics, Inc. presented t...

Larimar Therapeutics Q3 2024 Financial Update

In a report released today, Andreas Argyrides from Oppenheimer maintained a Buy rating on Larimar Therapeutics (LRMR – Research Report), with a pri...

Oppenheimer Keeps Their Buy Rating on Larimar Therapeutics (LRMR)

BIIB

LRMR

LXEO

PTCT

Press Releases

Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference

Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich's Ataxia

Comments

Larimar Therapeutics

Larimar Therapeutics (LRMR) Opzioni

Larimar Therapeutics (NASDAQ:LRMR) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO